Disease · HP_0000016

Urinary retention

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Urinary retention. Diseases, record HP_0000016. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000016

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Urinary retention; Open Targets
Open Targets ID: HP_0000016; Open Targets
Other names: Increased post-void residual urine volume; Open Targets
NCI Thesaurus: C50790; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 12 drugs, from DailyMed and TTD; Open Targets

Drugs12

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BETHANECHOL	CHEMBL1482	Small molecule	Approval	TTD	1	0	0	Drugs and targets
BETHANECHOL CHLORIDE	CHEMBL1768	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ALFUZOSIN	CHEMBL709	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
TAMSULOSIN HYDROCHLORIDE	CHEMBL1200914	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ONABOTULINUMTOXINA	CHEMBL1201574		Phase 2/3	ClinicalTrials.gov	2	2	1	Drugs and targets
BOTULINUM TOXIN TYPE A	CHEMBL4297862	Protein	Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
LETIBOTULINUMTOXINA	CHEMBL3707322		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
TAMSULOSIN	CHEMBL836	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
TRANEXAMIC ACID	CHEMBL877	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets
DUTASTERIDE	CHEMBL1200969	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 12

See all 12 drugs

Targets25

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA1A	Adrenergic receptor alpha-1	3	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha-1	3	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha-1	3	Adrenergic receptor alpha-1 agonist; Adrenergic receptor alpha-1 antagonist	Phase 3	https://conductscience.org/library/genes/146	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2/3	https://conductscience.org/library/genes/6616	Drugs and targets
CHRM2	Muscarinic acetylcholine receptor M2	2	Muscarinic acetylcholine receptor M2 agonist	Approval	https://conductscience.org/library/genes/1129	Drugs and targets
CHRM3	Muscarinic acetylcholine receptor M3	2	Muscarinic acetylcholine receptor M3 agonist	Approval	https://conductscience.org/library/genes/1131	Drugs and targets
KCNQ1	KCNQ (Kv7) potassium channel	1	KCNQ (Kv7) potassium channel opener	Unknown	https://conductscience.org/library/genes/3784	Drugs and targets
KCNQ2	KCNQ (Kv7) potassium channel	1	KCNQ (Kv7) potassium channel opener	Unknown	https://conductscience.org/library/genes/3785	Drugs and targets
KCNQ3	KCNQ (Kv7) potassium channel	1	KCNQ (Kv7) potassium channel opener	Unknown	https://conductscience.org/library/genes/3786	Drugs and targets
KCNQ4	KCNQ (Kv7) potassium channel	1	KCNQ (Kv7) potassium channel opener	Unknown	https://conductscience.org/library/genes/9132	Drugs and targets

1 to 10 of 25

See all 25 targets

Trials9

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01568918	Use of Tamsulosin to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery	Phase 3	90	2024-05-30	Postoperative Urinary Retention	TAMSULOSIN HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT02823431	Effect of Urethral Analgesia on Voiding	Not applicable	23	2018-07-27	Urethral Analgesia	LIDOCAINE	Its record names the disease	ClinicalTrials.gov
NCT00290030	ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH	Phase 3	800		Prostatic Hyperplasia, Acute Urinary Retention	ALFUZOSIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00336921	Alfuzosin for Treating Acute Urinary Retention	Phase 2	156		Acute Urinary Retention	ALFUZOSIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT04597372	Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery	Phase 2	154		Urinary Retention Postoperative	TAMSULOSIN	Its record names the disease	ClinicalTrials.gov
NCT00680680	Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker	Not applicable	20		Urinary Retention, Benign Prostatic Hyperplasia	DUTASTERIDE	Its record names the disease	ClinicalTrials.gov
NCT04555343	Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention	Phase 1/2	14		Urologic Diseases, Prostate Cancer, Bladder Cancer, Urinary Retention, Hematuria, Nurse Physician Relations, Nurse's Role, Patient Satisfaction	TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02428881	Botulinum Toxin A Injections in Patients With Fowler's Syndrome	Phase 2/3	10		Urinary Retention, Fowler's Syndrome	ONABOTULINUMTOXINA	Its record names the disease	ClinicalTrials.gov
NCT01462656	Risk of Urinary Retention With Retigabine		1		Epilepsy	EZOGABINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials5

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Tamsulosin vs Placebo: deaths from any cause	0 of 39	0 of 51	90	NCT01568918	Trial comparisons
Tamsulosin vs Placebo: Incidence of Postoperative Urinary Retention	11 of 39	20 of 51	90	NCT01568918	Trial comparisons
Tamsulosin vs Placebo: serious adverse events	0 of 39	0 of 51	90	NCT01568918	Trial comparisons
Analgesia Arm vs Placebo Arm: Number of Participants With Interrupted Urinary Flow Pattern During Micturition	4 of 11	0 of 12	23	NCT02823431	Trial comparisons
Analgesia Arm vs Placebo Arm: serious adverse events	0 of 11	0 of 12	23	NCT02823431	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
15291863	RESULT	1	PubMed
11743295	RESULT	1	PubMed
29300256	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0000016

GET https://conductscience.org/api/diseases/v1/HP_0000016/targets?page=2

API reference For AI assistants